106 related articles for article (PubMed ID: 21886516)
1. Characterizing medical care by disease phase in metastatic colorectal cancer.
Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
J Oncol Pract; 2011 May; 7(3 Suppl):25s-30s. PubMed ID: 21886516
[TBL] [Abstract][Full Text] [Related]
2. Characterizing medical care by disease phase in metastatic colorectal cancer.
Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP20-5. PubMed ID: 21711074
[TBL] [Abstract][Full Text] [Related]
3. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
[TBL] [Abstract][Full Text] [Related]
4. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Song X; Zhao Z; Barber B; Gregory C; Wang PF; Long SR
Curr Med Res Opin; 2011 Jan; 27(1):123-30. PubMed ID: 21128878
[TBL] [Abstract][Full Text] [Related]
6. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
8. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
[TBL] [Abstract][Full Text] [Related]
9. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
10. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
11. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
Dacosta Byfield S; Yu E; Morlock R; Evans D; Teitelbaum A
J Med Econ; 2013 Aug; 16(8):1071-81. PubMed ID: 23777222
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Qin A; Oster G
BMC Cancer; 2011 Jun; 11():250. PubMed ID: 21676243
[TBL] [Abstract][Full Text] [Related]
13. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
15. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
16. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
17. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
18. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
19. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
20. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
